The earnings call reflects a positive sentiment, with significant revenue growth, strategic advancements in the pipeline, and a clear path to profitability. While there are challenges with ZEJULA and supply constraints for XACDURO, these are outweighed by strong performance and promising future growth drivers, particularly with VYVGART.

Company Guidance -

Q3 2025

During the Zai Lab second quarter 2025 financial results conference call, the company reaffirmed its full-year revenue guidance of USD 560 million to USD 590 million and projected achieving profitability in the fourth quarter. Key growth drivers include the strong performance of VYVGART, with peak sales potential exceeding $1 billion, and potential near-term regulatory approvals for KarXT and TIVDAK in China. The company also highlighted its efficient commercial model and pipeline advancements, including the promising results of ZL-1310 in small cell lung cancer and the global R&D efforts for innovative therapies. Operating loss improved by 28% to $54.9 million, and on an adjusted basis, it reduced by 37% to $34.2 million. The company ended the quarter with a robust cash position of $832.3 million.

Strong Revenue Growth

Total revenue grew 9% year-over-year to $110 million in the second quarter, driven by higher sales of VYVGART, AUGTYRO, and XACDURO.

Profitability Milestone

Operating loss improved by 28% to $54.9 million, with an adjusted loss of $34.2 million, reflecting a year-over-year improvement of 37%. The company is on track to achieve profitability on an adjusted basis by the fourth quarter.

VYVGART Expansion and Success

Record levels of patient utilization for VYVGART in gMG with strong commercial execution. New national MG guidelines in China elevate VYVGART's positioning, with potential for over $1 billion in peak sales.

Pipeline Progress

Notable advancements in global R&D with promising results for ZL-1310 in small cell lung cancer and other neuroendocrine tumors, as well as progress in other pipeline programs like ZL-1503 and bemarituzumab.

Zai Lab (ZLAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZLAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.26 / -	-0.42	―	―	―
Aug 07, 2025	2025 (Q2)	-0.36 / -0.37	-0.82	54.88% (+0.45)
May 08, 2025	2025 (Q1)	-0.55 / -0.45	-0.55	18.18% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.65 / -0.80	-1.63	50.92% (+0.83)
Nov 12, 2024	2024 (Q3)	-0.78 / -0.42	-0.07	-500.00% (-0.35)
Aug 06, 2024	2024 (Q2)	-0.71 / -0.82	-1.25	34.40% (+0.43)
May 08, 2024	2024 (Q1)	-0.93 / -0.55	-0.51	-7.84% (-0.04)	―
Feb 27, 2024	2023 (Q4)	-0.86 / -1.63	-0.65	-150.77% (-0.98)
Nov 07, 2023	2023 (Q3)	-1.04 / -0.07	-1.68	95.83% (+1.61)	―
Aug 07, 2023	2023 (Q2)	-0.79 / -1.25	-1.44	13.19% (+0.19)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZLAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$38.72	$34.08	-11.98%
May 08, 2025	$28.36	$29.14	+2.75%
Feb 27, 2025	$35.07	$34.38	-1.97%
Nov 12, 2024	$31.09	$28.96	-6.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zai Lab (ZLAB) report earnings?

Zai Lab (ZLAB) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Zai Lab (ZLAB) earnings time?

Zai Lab (ZLAB) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZLAB EPS forecast?

ZLAB EPS forecast for the fiscal quarter 2025 (Q3) is -0.26.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing